Revolution Medicines, Inc. (RVMD) intrinsic value & 10-year financials
Revolution Medicines, Inc. (RVMD) has a Graham intrinsic value of $64.17 per share. At $177.96 on Oct 17, 2026, the stock trades 177% above that value. Over the last 9 fiscal years revenue shrank 10.5% a year to $0, with an average return on invested capital of -47.4%.
- Graham intrinsic value
- $64.17
- Share price (Oct 17, 2026)
- $177.96
- Price vs Graham value
- 177% above
- Market cap
- $33.8B
- Revenue (FY2025)
- $0
- Revenue growth (9-yr CAGR)
- -10.5%
- ROIC (10-yr avg)
- -47.4%
- Free cash flow (FY2025)
- -$913.7M
RVMD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$1.1B | -$5.95 | -$913.7M | — | -73.1% |
| FY2024 | $0 | -$600.1M | -$3.58 | -$567.7M | — | -45.1% |
| FY2023 | $11.6M | -$436.4M | -$3.86 | -$358.3M | -4207.1% | -53.9% |
| FY2022 | $35.4M | -$248.7M | -$3.08 | -$235.2M | -730.0% | -45.4% |
| FY2021 | $29.4M | -$187.1M | -$2.57 | -$153.7M | -639.7% | -39.4% |
| FY2020 | $43.0M | -$108.2M | -$2.01 | -$103.0M | -257.5% | -27.6% |
| FY2019 | $50.0M | -$47.7M | — | -$52.2M | -108.2% | — |
| FY2018 | $20.2M | -$41.8M | — | -$286.0K | -200.0% | — |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Revolution Medicines, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Revolution Medicines, Inc. has historically struggled to out-earn its cost of capital, averaging just -47.4% ROIC.
Revolution Medicines, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Revolution Medicines, Inc. is modeled at -10.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $64.17 per share.